Announcements Trials
Browse Landscape

Phase

Phase 1 14Phase 2 12Phase NA 11Phase EARLY_PHASE1 5Phase 1/2 5Phase 2/3 1

Status

Terminated 2Completed 2Recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

CNS 2Thoracic 1Sarcoma 1Lymphoid 1Genitourinary 1

Conditions

Brain Neoplasms 2Sarcoma, Ewing 1Prostatic Neoplasms 1Neoplasms 1Lymphoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 410Cyclophosphamide 394Carboplatin 306Gemcitabine 286Nivolumab 276Paclitaxel 274Cisplatin 252Radiotherapy 225Dexamethasone 210Bevacizumab 209fludarabine 192Docetaxel 187Rituximab 183Capecitabine 171Oxaliplatin 158Lenalidomide 157Fluorouracil 152Temozolomide 138Cytarabine 135Etoposide 128Irinotecan 124Cetuximab 123fludarabine phosphate 120Injections 118venetoclax 116Ipilimumab 115Doxorubicin 114Azacitidine 108130-nm albumin-bound paclitaxel 108Pemetrexed 107

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Interventional × alovudine × Clear all
NCT04989946 2026-01-28

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

University of Wisconsin, Madison

Phase 1/2 Recruiting
60 enrolled
Genitourinary

Prostatic Neoplasms

NCT04067115 2025-12-17

U01CA236220

Sarcoma Alliance for Research through Collaboration

Phase 1/2 Completed
37 enrolled
Sarcoma

Sarcoma, Ewing

NCT03276676 2024-12-27

[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors

University of Utah

Phase 1/2 Terminated
10 enrolled 7 charts
CNS

Brain Neoplasms

NCT01065805 2019-08-22

A Study to Demonstrate the Safety and Preliminary Efficacy of 18F-FLT in Patients With Solid Tumours or Lymphoma

AHS Cancer Control Alberta

Phase 1/2 Terminated
94 enrolled
CNSLymphoid

Brain Neoplasms, Lymphoma, Neoplasms

NCT00453362 2017-03-31

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Genentech, Inc.

Phase 1/2 Completed
88 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡